Advax enhances response to pandemic
avian influenza vaccine
Enhancement of IgG Antibody titers
by Advax to Recombinant H5 antigen
rH5
rH5+Advax *
0.0 0.2 0.4 0.6 0.8
Antibody Titers (OD)
Advax H1N1/2009 vaccine approach
• Recombinant H1/2009 HA (Protein Sciences Corporation)
combined with Advax adjuvant
• Vaccine produced and ready for clinical trials within 6
weeks of pandemic declaration
• Trials commenced in Adelaide 20 July 2009 - first human
H1N1/09 trial
• Over 3 weeks recruited ~281 adults aged 18-70 including
subjects with chronic disease (only excluded children and
pregnant women)
Commercial in Confidence
H1N1/2009 vaccine results
• 6 groups: 3, 11 and 45ug HA H1N1 doses +/1 Advax
adjuvant
• PSC H1N1 antigen was extremely tolerated
• Excluding local tenderness in mild category, local and
systemic AE rates were no different between adjuvanted
and nonadjuvanted groups
• Baseline H1N1 seroprotection rate (~5%) – no age
relationship
• Dose-dependent seroprotection (~40% across study) maximal
at 45ug HA dose with Advax
• Advax significantly increased seroprotection rates (RR ~1.6)
vs HA alone
• Response highly age dependent, with low response in
subjects >50 unless received vaccine with Advax
Commercial in Confidence
Summary
• PSC’s recombinant HA technology able to
deliver new pandemic vaccine extremely
fast
• HA antigen extremely well tolerated
• In situations where low immunogenicity
may be encountered, the PSC antigen can
be successfully complemented with Advax
adjuvant technology